MEN 1611

Drug Profile

MEN 1611

Alternative Names: CH5132799; MEN-1611; PA-799

Latest Information Update: 25 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chugai Pharma Europe
  • Developer Berlin Chemie; Chugai Pharma Europe
  • Class Antineoplastics
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Breast cancer; Solid tumours

Most Recent Events

  • 19 Oct 2018 Phase-I clinical trials in Breast cancer (Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or greater) in Netherlands, United Kingdom, France, Belgium, Spain and Italy (PO)
  • 19 Sep 2018 MEN 1611 is still in phase I trials for Solid tumours in United Kingdom
  • 21 Apr 2018 Pharmacodynamics data from a preclinical study in Solid tumour presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top